Program
tavapadon
Also written as “Tavapadon”, “PF-06649751” and “0.5 mg PF-06649751”.
Its studies are mostly in Parkinson Disease · Renal Insufficiency, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| AbbVie | 110 open or running | phase 3since Dec 13, 2019 | Dec 13, 2019 | none ahead |
| Pfizer | 90 open or running | phase 2since Jan 29, 2016 | Nov 5, 2013 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 4 studies since Nov 5, 2013.
- Feb 20, 2015Phase 1 study in Parkinson DiseasePfizer · NCT02373072 · 18 enrolled · United States, Belgium
- Jan 29, 2016Phase 2 study in Parkinson DiseasePfizer · NCT02687542 · 108 enrolled · United States, Canada, France and more
- Jul 25, 2016Phase 2 study in Parkinson DiseasePfizer · NCT02847650 · 57 enrolled · United States, France, Germany and more
- Apr 7, 2017Phase 1 study in HealthyPfizer · NCT03121664 · 11 enrolled · Belgium
- Jun 9, 2017Phase 2 study in Parkinson DiseasePfizer · NCT03185481 · 5 enrolled · United States
- Dec 13, 2019AbbVie's first study: phase 3 study in Parkinson DiseaseNew to AbbVieAbbVie · NCT04201093 · 529 enrolled · United States, Australia, Bulgaria and more
- Jan 7, 2020Phase 3 study in Parkinson DiseaseAbbVie · NCT04223193 · 304 enrolled · United States, Australia, France and more
- Jan 22, 20202 phase 1 studiesAbbVie · NCT04241393, NCT04295642
- Sep 2, 2020Phase 3 study in Parkinson DiseaseAbbVie · NCT04542499 · 507 enrolled · United States, Australia, Bulgaria and more
- Feb 12, 2021Phase 3 study in Parkinson DiseaseAbbVie · NCT04760769 · 992 enrolled · United States, Australia, Bulgaria and more
- May 30, 20222 phase 1 studiesAbbVie · NCT05404542, NCT05404529
- Oct 12, 2022Phase 1 study in Parkinson DiseaseAbbVie · NCT05581823 · 16 enrolled · United States
- Nov 2, 2022Phase 1 study in Parkinson DiseaseAbbVie · NCT05610189 · 25 enrolled · United States
- Mar 20, 2025Phase 1 study in Healthy VolunteerAbbVie · NCT06895356 · 83 enrolled · United States
TargetBeta
“Dopamine D1 receptor partial agonist; Dopamine D5 receptor partial agonist”ChEMBL 37, by rule
Studies
All 20 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT06895356Healthy Volunteer · United States | 1 | Completed | AbbVie | Jun 16, 2025 | 83 |
| NCT05610189Parkinson Disease · United States | 1 | Completed | AbbVie | Dec 12, 2023 | 25 |
| NCT05581823Parkinson Disease · United States | 1 | Completed | AbbVie | Jan 27, 2023 | 16 |
| NCT05404542Renal Insufficiency · United States | 1 | Completed | AbbVie | Aug 14, 2023 | 14 |
| NCT05404529Hepatic Impairment · United States | 1 | Completed | AbbVie | Jan 24, 2023 | 32 |
| NCT04760769Parkinson Disease · United States, Australia, Bulgaria and more | 3 | Completed | AbbVie | Dec 1, 2025 | 992 |
| NCT04542499Parkinson Disease · United States, Australia, Bulgaria and more | 3 | Completed | AbbVie | Jan 29, 2024 | 507 |
| NCT04295642Parkinson Disease · United States | 1 | Completed | AbbVie | Jul 23, 2021 | 24 |
| NCT04241393Healthy Subjects · United States | 1 | Completed | AbbVie | Nov 8, 2020 | 12 |
| NCT04223193Parkinson Disease · United States, Australia, France and more | 3 | Completed | AbbVie | Oct 1, 2024 | 304 |
| NCT04201093Parkinson Disease · United States, Australia, Bulgaria and more | 3 | Completed | AbbVie | Jun 28, 2024 | 529 |
| NCT03185481Parkinson Disease · United States | 2 | Terminated | Pfizer | Oct 24, 2017 | 5 |
| NCT03121664Healthy · Belgium | 1 | Completed | Pfizer | Sep 14, 2017 | 11 |
| NCT02847650Parkinson Disease · United States, France, Germany and more | 2 | Terminated | Pfizer | Jan 29, 2018 | 57 |
| NCT02687542Parkinson Disease · United States, Canada, France and more | 2 | Terminated | Pfizer | Nov 10, 2017 | 108 |
| NCT02373072Parkinson Disease · United States, Belgium | 1 | Completed | Pfizer | Feb 2016 | 18 |
| NCT02262767Healthy · Belgium | 1 | Completed | Pfizer | Dec 2014 | 9 |
| NCT02224664Parkinson Disease · United States, Belgium | 1 | Completed | Pfizer | Mar 2016 | 50 |
| NCT02066909Healthy · United States | 1 | Completed | Pfizer | Apr 2015 | 77 |
| NCT01981694Healthy · United States | 1 | Completed | Pfizer | Feb 2014 | 18 |
How it is read
Names in the registry
- “Tavapadon”, 10 entries
- “PF-06649751”, 9 entries
- “0.5 mg PF-06649751”, 2 entries
- “CVL-751”, 1 entry
- “PF-06649751 low dose (1 mg QD)”, 1 entry
Codes read as this program: PF06649751.
Conditions, from the studies’ own filings
- Parkinson Disease, 12 studies
- Renal Insufficiency, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.